In the study by Ho et al. (2020), no noticeable differences in ORR existed between virally infected and uninfected HCC patients receiving PD-1/PD-L1 inhibitors, and viral status could not be a criterion for PD-1/PD-L1 inhibitors. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.